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Abstract
Introduction: Patients with classical congenital adrenal hyperplasia (CAH) have increased cardiovascular risk, but the vascular and cardiac 
function during longitudinal corticoids replacement therapy is not known thoroughly.
Material and methods: Cross-sectional study of 19 Caucasian adults with CAH (age 23.7 ± 3.8 years; twelve males) compared to 20 healthy 
volunteers matched for origin, sex, age, and body mass index (BMI). All of the participants were assessed for flow mediated dilatation 
of the brachial artery (FMD), intima-media thickness of the common carotid artery (cIMT) and common femoral artery (fIMT), standard 
echocardiography, and global longitudinal left ventricular function using two-dimensional speckle-tracking echocardiography (LSTE). 
Results: The patients with CAH, compared with controls, had decreased FMD (9.4 ± 3.9 vs. 19.8 ± 5.2; p < 0.01), and the difference was 
still significant after correction for potential confounders. cIMT and fIMT were higher in the CAH group at baseline (for cIMT 0.47 ± 0.4 
mm vs. 0.40 ± 0.03 mm; p < 0.01, for fIMT 0.47 ± 0.05 mm vs. 0.41 ± 0.04 mm; p < 0.01) but not after correction for potential confound-
ers. The CAH subjects, compared with controls, had normal or similar left ventricular (LV) ejection fraction and LV mass index. The mean 
absolute value of LSTE differed in the CAH patients compared with controls (–20.5% ± 1.2 vs. –22.5% ± 1.7; p < 0.01), but it was still 
within the normal range.
Conclusions: Young adults with CAH and glucocorticoid long-lasting treatment had impaired FMD, an insignificant increase of IMT, and 
subclinical changes in LV diastolic function in echocardiography. (Endokrynol Pol 2017; 68 (5): 505–511)
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Streszczenie
Wstęp: Pacjenci z klasyczną postacią wrodzonego przerostu nadnerczy (congenital adrenal hyperplasia, CAH) charakteryzują się zwiększo-
nym ryzykiem sercowo-naczyniowym, jednak funkcja naczyń oraz serca podczas długotrwałej substytucyjnej terapii glikokortykoidami 
nie została jednoznacznie określona.
Pacjenci i metody: W badaniu obserwacyjnym, 19 dorosłych rasy białej z CAH (wiek 23,7 ± 3,8 roku; 12 mężczyzn) porównywano 
z 20 zdrowymi ochotnikami dobranymi pod względem pochodzenia, płci, wieku i współczynnika masy ciała. U wszystkich uczestni-
ków badania oceniono wazodylatację tętnicy ramiennej indukowaną przepływem (flow mediated dilatation, FMD), grubość kompleksu 
intima–media tętnicy szyjnej wspólnej (intima-media thickness of the common carotid artery, cIMT) oraz tętnicy udowej (common femoral artery, 
fIMT) wspólnej oraz oceniono odkształcenie lewej komory przy zastosowaniu techniki śledzenia markerów akustycznych (longitudinal 
speckle-tracking echocardiography, LSTE).
Wyniki: U pacjentów z CAH w porównaniu z grupą kontrolną zaobserwowano mniejszą wartość FMD (9,4 ± 3,9 vs. 19,8 ± 5,2; p < 0,01) 
i różnica ta była nadal istotna po uwzględnieniu wpływu średnicy tętnicy ramiennej. Wyjściowo cIMT i fIMT były większe u pacjentów 
z CAH (cIMT 0,47 ± 0,4 mm vs. 0.40 ± 0,03 mm, p < 0,01; fIMT 0,47 ± 0,05 mm vs. 0,41 ± 0,04 mm, p < 0,01), ale nie po uwzględnieniu 
klasycznych czynników ryzyka sercowo-naczyniowego. Frakcja wyrzutowa oraz masa lewej komory w obu grupach były podobne. 
Średnia wartość LSTE była różna u pacjentów z CAH z porównaniu z grupą kontrolną (–20,5 ± 1,2% vs. –22,5 ± 1,7%, p < 0,01), ale nadal 
pozostawała w granicach normy.
Wnioski: U młodych dorosłych z CAH długotrwale leczonych glikokortykosteroidami FMD jest upośledzona, występuje nieistotne po-
grubienie cIMT i fIMT oraz podkliniczne zmiany w funkcji rozkurczowej serca w echokardiografii. (Endokrynol Pol 2017; 68 (5): 505–511)
Słowa kluczowe: wrodzony przerost nadnerczy, wazodylatacja indukowana przepływem, grubość kompleksu intima–media, funkcja lewej 
komory
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Introduction
Congenital adrenal hyperplasia (CAH) is a group of 
autosomal recessive disorders characterised by a defect 
in cortisol biosynthesis mainly due to 21-hydroxylase 
deficiency (21-OHD) [1]. About 1 in 10,000–18,000 
children are born with CAH. The goal of treatment is 
to return hormone levels to normal, or near normal, 
which is accomplished by taking a form of cortisol. 
Optimal therapeutic regimens are difficult to achieve, 
and often complications related to glucocorticoid and/ 
/or androgen excess arise. Therefore, abnormalities in 
lipid and glucose metabolism, body fat mass, insulin, 
leptin, and blood pressure levels have been reported 
in patients with 21-OHD, with potential long-term 
complications in life [2–5]. Overtreatment or undertreat-
ment can affect cardiac and vascular function. There is 
increasing evidence that endothelial dysfunction and 
vascular changes are precursors of clinically detect-
able atherosclerosis and improve prediction of future 
cardiovascular (CV) events [6, 7]. It has been described 
that adolescent children with CAH present vascular 
dysfunction measured by flow-mediated dilatation of 
the brachial artery (FMD) and increased carotid intima 
media thickness (cIMT) [8–11]. cIMT remains higher in 
adults [3, 12]. The echocardiographic changes in young 
patients with CAH have been poorly described; there is 
only limited information concerning the increase of the 
left ventricular mass index (LVMI) and left ventricular 
(LV) dysfunction compared with controls [11, 13]. Poor 
hormonal control, especially overtreatment, is common 
among patients with CAH, and it seems to determine 
the higher rate of CV events in this group [14]. The 
influence and the results of long-term corticosteroid 
and fludrocortisone replacement therapy on vascular 
and cardiac function in adults with CAH have not been 
established yet.
Material and methods
We included into cross sectional study 19 young Cauca-
sian adults with CAH, with mean age 23.7 ± 3.8 years, 
(12 males), all salt wasting (SW) due to 21-OHD, who 
were treated at the Department of Endocrinology in 
Rybnik, Poland for the first time. All of the participants 
signed a written, informed consent after receiving in-
formation about the study. The diagnosis of CAH was 
based on clinical and biochemical criteria in new-borns 
and all the patients had experienced a SW adrenal crisis 
in the neonatal period. The individuals had been treated 
continuously from the time of diagnosis and none of 
them was cured in utero with dexamethasone. The 
accuracy of the therapy was monitored periodically 
on the basis of clinical and laboratory data, according 
to the guidelines [15, 16]. All the patients received 
corticoid replacement therapy, one woman took oral 
contraceptive pills, and none of the patients used ad-
ditional medication. The control group constituted 20 
healthy volunteers without cardiovascular diseases 
(CVD) matched for origin, age, and body mass index 
(age 23.2 ± 2.6 years; 12 males), enrolled in the same 
region of Poland.
Data sources
The clinical characteristics of study patients included 
medical history (family history, concomitant diseases, 
present pharmacotherapy, smoking status) and physi-
cal examination: resting blood pressure (BP), heart rate 
(HR), body mass index (BMI), and height, waist, and 
hip circumference (WHR) using standard methods. 
Anthropometric measurements were obtained in the 
morning. The mean of three BP measurements taken 
with sphygmomanometer on separate occasions was 
considered.
Laboratory tests
Blood samples were drawn from the peripheral vein 
of supine individuals at 6:00 a.m. for measurements 
of hormones. Total cholesterol (T-Ch), high-density 
lipoprotein cholesterol fractions (HDL-Ch), low-density 
lipoprotein cholesterol fractions (LDL-Ch), triglyce-
rides (TGL), creatinine, and serum glucose levels, were 
measured using routine methods. The oral glucose 
tolerance test (OGTT) after an overnight fast for at 
least 10 h and after oral administration of 75 g glucose 
was performed. Serum levels of total testosterone (TT), 
17-hydroxyprogesterone (17-OHP), and androstenedi-
one were measured using an electrochemiluminescence 
immunoassay (Roche Diagnostics Manheim, Germany). 
Plasma renin activity (RRA) was measured using radio-
immunoassay. Glucocorticoid dose equivalencies were 
calculated based on their growth-suppressing effects in 
comparison to hydrocortisone. The prednisone dose 
was multiplied by five, and the dexamethasone dose 
was multiplied by 80 [17, 18]. The biochemical CVD 
risks factors were performed in patients and controls. 
Definitions
17-OHP was considered suppressed if below 100 ng/dL. 
Androstenedione, TT, and PRA were categories as sup-
pressed, normal, or elevated based on the respective 
sex-specific normal ranges. The overweight was defined 
as BMI between 25 and 29.9 kg/m2, and obesity at minu-
mum 30 kg/m2. Metabolic syndrome was recognised 
according to the International Diabetes Federation 
(IDF) definition [19]. Impaired glucose tolerance (IGT) 
was categorised as two-hour glucose levels of 7.8 to 
11.0 mmol/L during the OGTT. Central obesity was 
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recognised when waist circumference was ≥ 94 cm 
(male) and ≥ 80 cm (females); dyslipidaemia was 
identified as follows: T-Ch > 5.0 mmol/L or LDL-Ch 
> 3.0 mmol/L or HDL-Ch < 1.0 mmol/L (male), 
< 1.2 mmol/L (female) or TG > 1.7 mmol/L. The normal 
range left mass index (LVMI) was defined as < 125 g/m2 
(male) and < 110 g/m2 (female). The normal left ven-
tricular ejection fraction (LVEF) wad defined as equal 
to or more than 55% [20].
Ultrasound assessment
Echocardiography was performed in all of the patients 
according to the guidelines of the European Society of 
Echocardiography. Two-dimensional (2D) M-mode tran-
sthoracic echocardiography (TTE) was used in all patients 
to measure the LV dimensions in the left parasternal 
long-axis view. The values of LV end-diastolic volumes 
(LV EDV) and LV end-systolic volumes (LV ESV) were 
measured, and the LVEF was obtained using Simpson’s 
method [21]. The left ventricular mass (LVM) was calcu-
lated from the measurement of LV by using the truncated 
ellipsoid methods by 2D echocardiography, in grams [22]. 
The LVMI representing LVM corrected for body surface 
area (BSA) was calculated. Mitral inflow was assessed in 
the apical four-chamber view, using pulsed-wave Dop-
pler echocardiography, with the Doppler beam aligned 
parallel to the direction of flow and the sample volume 
at the leaflet tips. Measurements included peak E and 
A velocities. Doppler tissue imaging of the mitral annulus 
was obtained from the apical four-chamber view using 
a 1–2-mm sample volume placed in the septal and lateral 
sides of the mitral annulus valve, and then the average 
value was obtained. The ratio E/e’ including the mitral 
inflow E velocity to tissue Doppler was obtained as 
a marker of LV filling pressure [23].
Myocardial tissue deformation was analysed offline 
using commercially available software (QLAB Philips) 
using recorded 2D grey-scale images. The software 
analysed the speckles within the myocardium and 
calculated segmental strain. The peak longitudinal 
strain echocardiography (STE) was calculated as the 
average of peak values for each of the segments in the 
apical two-chamber, four-chamber, and five-chamber 
views. The values of inter- and intra-observer varia-
bility in analysis of patients’ recordings were 90% and 
94%, respectively. Among all the strain parameters, the 
longitudinal strain is more reproducible than the radial 
and circumferential strain and rotation. Similarly, the 
global strain has much better reproducibility than the 
segmental strain.
Flow-mediated dilatation
The measurements of the brachial artery FMD were 
conducted in a quiet, temperature-controlled room 
between 9.00 and 11.00 am. Patients underwent evalu-
ation after at least 10-minute rest in a supine position. 
Experienced investigators took measurements in 
a B-mode presentation using a high-frequency ultra-
sound system (Philips HD 15) equipped with vascular 
software for two-dimensional (2D) imaging, colour 
and spectral Doppler, an internal electrocardiogram 
monitor, and a high-frequency vascular transducer 
(multiple-frequency: 7–10 MHz). The brachial artery 
diameter (Bad) of the dominant forearm (in the case of 
the radial access the secondary artery) was visualised 
above the antecubital fossa in a longitudinal plane, with 
a sphygmomanometer cuff on the proximal portion of 
the arm. The brachial artery diameter was described 
as a minimal distance between ‘m’ lines, from the an-
terior to the posterior wall of the artery. Images were 
acquired with ECG gating, with measurements made 
in end diastole, which corresponds to the onset of the R 
wave. The study was performed in three stages: stage 1: 
baseline brachial artery diameter and flow measure-
ments were taken, and the mean average was calculated 
for each subject; stage 2: the sphygmomanometer cuff 
was inflated to 200 mmHg to occlude arterial inflow for 
3 min; stage 3: brachial artery diameter and blood flow 
were obtained during 50–60 seconds after cuff deflation, 
and the mean of the values were calculated. Taking 
these two measurements into consideration (baseline 
and after cuff deflation), the percentage increase in the 
artery diameter in comparison to baseline results was 
calculated — FMD [24, 25]. The values of inter- and 
intra-observer variability in analysis of patients’ record-
ings were 89% and 90%, respectively. Because FMD 
mostly depends on Bad, the FAD x Bad index was also 
calculated [26].
Intima media thickness of the common carotid 
artery and common femoral artery
Intima media thickness of the common carotid artery 
was obtained with the patient lying in the supine po-
sition (Philips HD15). cIMT measurements were per-
formed over a distance of 10 mm on the posterior wall 
of each common carotid artery (CCA) before the bulb. 
Three different longitudinal images (anterior oblique, 
lateral, and posterior oblique) for each CCA were pro-
duced. In the case of the plaque in the measurement 
side, which was defined as a localised protrusion into 
the vessel lumen with thickening of the vessel wall of 
> 50% compared to the adjustment cIMT, the meas-
urement was passed over [27]. All the measurements 
were conducted in the end diastolic phase of the car-
diac cycle. cIMT-analysis was obtained by automatic 
technique using QLAB Philips system after completed 
examination, and presented as a mean value from six 
measurements. QLAB’s IMT measurement plug-in 
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was used to increase the consistency and reliability of 
cIMT measurements. The same technique was used to 
evaluate the intima media thickness of the common 
femoral artery (fIMT). 
Statistical analysis
Statistical analysis was performed by the application of 
MedCalc Statistical Software version 14.12.0 (MedCalc 
Software bvba, Ostend, Belgium). All of the text and 
table results are expressed as mean ± standard devia-
tion (SD) or median and interquartile range (IQR) or 
number and percentage. The normal distribution of the 
results was analysed using the Kolmogorov-Smironov 
test. In the case of abnormal distribution a logarithmic 
transformation was introduced. The calculation of Coef-
ficient of Variation (CV) from duplicate measurements 
was made. Baseline clinical parameters and the results 
of accessory investigations were compared using the 
t-test or U Mann-Whitney test. Categorical variables 
were compared using Fisher’s exact test. To determine 
the relationship between the dose of corticosteroids 
and FMD, cIMT, and fIMT Pearson correlations after 
logarithmic transformation were used. To compare the 
FMD and intima media thickness (IMT) values between 
groups after adjusting for potential cofounders, the 
ANCOVA test with Bonferroni correction was intro-
duced. Statistical significance was defined as p < 0.05.
Results
Treatment and adrenal hormone status
As expected, all the patients were treated with the glu-
cocorticoid: 11 (58%) of them received hydrocortisone, 
seven (37%) hydrocortisone and dexamethasone, and 
one (5%) only dexamethasone. The mean glucocorticoid 
equivalence dose was 20.0 ± 6.0 mg/m2. Seventy-three 
per cent (14 patients) were cured by fludrocortisone, 
with median dose 29 µg/m2 (IQR: 26–58). 
Overtreatment or undertreatment was common in 
the analysed group of patients. Only 36% had accept-
able hormonal status based on early morning 17-OHP 
concentration between 100 and 1200 ng/dL (mean 201 
± 211 ng/dL). Approximately half of the patients had 
androstenedione level in normal range (median 2.82 
ng/ml, IQR: 0.75–13.9). In addition, the elevated testos-
terone concentration adjusted for sex was detected in 
three patients (median 3.35 ng/mL ± 2.9). The PRA was 
in normal range only in 30% of the patients.
Cardiovascular risk factors
Eleven patients (58%) had normal BMI, five (26%) were 
overweight, while three (16%) were obese. The central 
obesity was recognised in three (15%), individuals 
and metabolic syndrome according IDF criteria in two 
patients. Dyslipidaemia was present in 10 (57%) patients, 
nobody had plasma fasting glucose ≥ 5.6 mmol/L, but 
three patients exhibited IGT in OGGT. CAH patients did 
not statistically differ with controls in CVD risk factors, 
and the global results are presented in Table I and II.
Vascular changes
The patients with CAH, compared with the control 
group, had decreased mean FMD (9.4 ± 3.9 vs. 19.8 ± 
5.2; p < 0.01), and the difference was still significant 
after correction for potential confounders such as: 
brachial artery diameter, age, sex, BMI, total cholesterol 
level, smoking status, the dose of corticosteroid, and 
fludrocortisone (mean 9.2; SE 2.6 vs. 19.4; SE 2.4; p = 
0.03). The FMD x Bad index was also different in the 
CAH group (p < 0.1). The cIMT and fIMT was higher 
in the CAH group at baseline (for cIMT 0.47 ± 0.4 mm 
vs. 0.40 ± 0.03 mm; p < 0.01, for fIMT 0.47 ± 0.05 mm 
vs. 0.41 ± 0.04 mm; p < 0.01). The difference was not 
significant after correction for potential confounders 
such as: age, sex, BMI, the dose of corticosteroid and 
fludrocortisone, total cholesterol level, and smoking 
status (for cIMT 0.45 mm, SE 0.02 vs. 0.42 mm, SE 0.02; 
p = 0.46, for fIMT 0.46 mm, SE 0.02 vs. 0.41 mm, SE 0.02; 
p = 0.14). There was no correlation between cumula-
tive steroids dose and cIMT, fIMT, and FMD (Table III). 
Echocardiographic changes
All the CAH subjects compared with controls had 
normal and similar LVEF: 64 ± 4 vs. 65 ± 4; p = 0.60 
and LVMI: 90.4 g/m2 ± 15 vs. 87.4 g/m2 ± 12; p = 0.50. 
Table I. Clinical characteristics of the study group
Tabela I. Charakterystyka kliniczna badanej grupy
Variables CAH (N = 19) Control (N = 20) P value
Age (years) 23.7 ± 3.8 23.2 ± 2.6 0.60
BMI [kg/m²] 24.9 ± 5.1 23.5 ± 3.3 0.30
High [cm] 162 ± 8 168 ± 7 0.03
Weight [kg] 63.3 ± 13.6 66.4 ± 12.7 0.80
Waist to hip ratio 0.84 ± 0.05 0.82 ± 0.08 0.31
SBP [mmHg] 109 ± 12 111 ± 9 0.63
DBP [mmHg] 69 ± 9 72 ± 7 0.29
TCh [mmol/l] 4.5 ± 0.9 4.8 ± 0.8 0.21
LDL-Ch [mmol/l] 2.7 ± 0.7 2.9 ± 0.6 0.49
HDL-Ch [mmol/l] 1.4 ± 0.3 1.5 ± 0.3 0.29
TG [mmol/l] 1.3 ± 0.6 1.0 ± 0.5 0.13
Active smoking 2 (11%) 3 (15%) 1.0
Abbreviations: CAH, congenital adrenal hyperplasia; BMI, body mass index; SBP, 
systolic blood pressure; DBP, diastolic blood pressure; TCh, total cholesterol; 
LDL-Ch, low density lipoprotein cholesterol; HDL-Ch, high densisty lipoprotein 
cholesterol; TG, triglicerydes
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Doppler tissue imaging of the mitral annulus was lower 
in the CAH group: 14.5 ± 3.3 cm/s vs. 16.8 ± 3.0 cm/s, 
p = 0.03, but the value was still within the normal 
range. The mean absolute value of LSTE differed in the 
CAH patients compared with controls (–20.5% ± 1.2 vs. 
–22.5% ± 1.7; p < 0.01) (Table IV).
Correlation results
We found the positive correlation between fIMT and 
TT in the study group (r = 0.43; p = 0.04), for cIMT 
(r = 0.33; p = 0.10). No additional significant correlation 
emerged between 17-OHP, androstenedione, cumula-
tive glucocorticoids doses, and FMD, FMDxBad index, 
cIMT, fIMT, and echocardiography parameters.
Discussion
The study population did not statistically differ in classic 
CVD risk factors, and metabolic profiles were compa-
rable to apparently healthy individuals in the same 
region of Poland [28]. Despite this fact, we observed 
more vascular changes in the study group. Harrington 
et al. described impaired FMD in CAH adolescents 
as being comparable to obese control patients [8]. 
The issue of impaired FMD in overweight has not 
been solved explicitly. In CAH patients probably the 
reason for endothelial dysfunction is not the obesity 
itself, but the higher proportion of proinflammatory 
visceral adipose tissue to subcutaneous adipose tissue 
and insulin resistance [4, 10, 29], as well as the excess 
of androgens: TT and androstenedione influences the 
endothelial function. Sander et al. revealed in a small 
group of young hypogonadal but otherwise healthy 
men, that receiving testosterone depot in short-term 
follow-up caused a significant decrease in FMD [30]. 
Similarly, self-administration of anabolic-androgenic 
steroids was associated with endothelial dysfunction 
in male body builders [31]. The metabolic profile of 
the analysed group was not optimal, which, unfortu-
nately, is quite common in the CAH population [14]. 
The question of whether optimal hormonal status of 
CAH patients improves endothelial function, which is 
sensitive to minor homeostasis disturbances, remains 
unanswered [32].
Ultrasound assessment of cIMT is a well-established 
examination that perfectly correlates with CV risk 
estimated by means of Systematic COronary Risk 
Evaluation (SCORE scale), which is the perfect tool for 
Table II. Cardiovascular risk factors in the study group
Tabela II. Czynniki ryzyka sercowo-naczyniowego w badanej 
grupie
Variables CAH (N = 19) Control (N = 20) P value
Active smoking 2 (11%) 3 (15%) 1.0
Dyslipidemia 10 (53%) 9 (45%) 0.75
Hypertension 0 0 —
IGT 4 (21%) 1 (5%) 0.18
Central obesity 3 (16%) 2 (10%) 0.66
Normal weight/  
/overweight/ 
/obesity
11/5/3 
(58/26/16%)
13/6/1  
(65/30/5%)
0.54
Metabolic 
symdrome
2 (11%) 2 (10%) 1.0
Values are given as number and percentage. Abbreviations: CAH, congenital 
adrenal hyperplasia; IGT, impaired glucose tolerance
Table III. Value of FMD, cIMT, fIMT in the study group
Tabela III. Wartość FMD, cIMT w badanej grupie
Variables Overall Control CAH P value
n = 39 n = 19 
(48%)
n = 20 
(52%)
Bad [mma] 3.2 ± 0.45 3.2 ± 0.40 3.2 ± 0.51 0.88
FMDa 13.5 ± 6.7 9.4 ± 3.9 19.8 ± 5.2 < 0.01
FMDb  — 9.2; 2.6 19.9; 2.4 0.03
FMDxBad 
indexa
46 ± 21 30 ± 13 62 ± 16 < 0.01
cIMT [mma] 0.44 ± 0.05 0.47 ± 0.04 0.40 ± 0.03 < 0.01
cIMT [mmc]  — 0.45; 0.02 0.42; 0.02 0.46
fIMT [mma] 0.43 ± 0.05 0.47 ± 0.05 0.41 ± 0.04 < 0.01
fIMT [mmc]  — 0.46; 0.02 0.41; 0.02 0.14
aValues are given as mean ± SD or median (interquartile range) 
bp value after correction for potential confounders such as: Bad, age, sex, BMI, 
the dose of corticosteroid and fludrocortisone, total cholesterol level, smoking 
status, values are given as estimated marginal means and standard error 
cp value after correction for potential confounders such as: age, sex, BMI, the 
dose of corticosteroid and fludrocortisone, total cholesterol level, smoking 
status, values are given as estimated marginal means and standard error
Abbreviations: CAH, congenital adrenal hyperplasia; Bad, brachial artery 
diameter; FMD, flow mediated dilatation; cIMT, intima-media thickness of 
common carotid artery, fIMT, intima-media thickness of common femoral artery
Table IV. Echocardiographic characteristics of the study group
Tabela IV. Charakterystyka echokardiograficzna w badanej 
grupie
Variables CAH (N = 19) Control (N = 20) P value
LVEF (%) 64 ± 4 65 ± 4 0.60
LVMI [g/m2] 90.4 ± 15 87.4 ± 12 0.50
e’ [cm/s] 14.5 ± 3.3 16.8 ± 3 0.03
E/e’ ratio 5.9 ± 1.6 4.9 ± 0.95 0.08
LSTE (%) –20.5 ± 1.2 22.5 ± 1.7 < 0.01
Abbreviations: CAH, congenital adrenal hyperplasia; LVEF, left ventricular ejection 
fraction; LVMI, left ventricular mass index, e’ average value of the Doppler tissue 
imaging of the mitral annulus; E/e’, the ratios include the mitral inflow E velocity 
to tissue Doppler e'; LSTE, longitude speckle-tracking echocardiography
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predicting the risk of CV death [27]. The present study 
revealed increased cIMT and fIMT in CAH patients, 
similarly to other results [3, 11, 12], but after correction 
for classic CVD risk factors and substitution doses of 
steroids the value was not statistically important. This 
reveals the possible relationship between IMT and glu-
cocorticoid replacement therapy. Moreover, the IMT of 
all the patients was within the normal limits, and any 
atherosclerotic plaque was detected in the common 
femoral artery as well as in the CCA. Additionally, IMT 
values of our patients, measured by an automatic meth-
od, were substantially lower than data from previous 
publications, in which IMT was estimated by operators, 
who might spontaneously overestimate IMT values [3].
We revealed positive correlation between cIMT and 
TT in CAH patients for the first time. In 2015 Khazai et 
al. in a male cohort demonstrated that lower TT levels 
compared to higher levels after adjustment for CVD risk 
factors were associated with lower cIMT [33]. 
Children with CAH had recognised increased LVMI 
[11], but we did not observe such a relationship in 
our adult population. Bofing et al., in CAH children, 
especially SW, observed transient-hypertension, but 
the prevalence of hypertension decreased with age [5], 
which might be responsible for transient left ventricular 
mass increase. Their participants had normal LVEF but 
statistically worse left ventricular regional myocardial 
function when using two-dimensional speckle tracking 
echocardiography in comparison to controls. The clini-
cal importance of this difference remains unknown. STE 
can accurately detect subtle changes in the myocardial 
function and is much more sensitive to the early myo-
cardial damage than any of the other deformation pa-
rameters [34]. It has been demonstrated that new-borns 
with CAH showed evidence for cardiac dysfunction at 
baseline, which reversed with corticosteroid replace-
ment therapy [35].
Our study has some limitations, among which the 
foremost is the small number of participants, so the 
power of the study was inappropriate for many clini-
cal endpoints. Moreover, during inclusion the patients 
were suboptimally treated. On the other hand, the 
patients came from the same region of Poland and so 
had similar CVD risk factors associated with ethnicity, 
diet, and pollution of the natural environment.
In conclusion, we underline that CAH are prone to 
CVD much more than could be due to classic risk scales. 
In addition, the echocardiographic changes, especially 
in diastole function, might be a signal for development 
of heart failure in older age. The question of whether 
optimal therapy might reverse this trend, remains un-
answered, especially as recommended drugs such as 
aldosterone antagonists and angiotensin-converting- 
-enzyme inhibitors may be not effective in CAH patients.
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